Immune to Cancer: The CRI Blog
-
Longboarding in the Fight Against Cancer with James McGary
Professional longboarder James is going the distance: he's longboarding from Seattle to New York City to raise…
-
Pam G’s Immunotherapy Story
Lung Cancer | Diagnosed 2013 I would not be alive today if it were not for this… -
CRI Scientists Honored With Five AACR Awards
Carl June, Elizabeth Jaffee, James Allison, David Baltimore, and Owen Witte pick up prestigious cancer awards.
-
What Cancer Patients Need to Know About the Opdivo Approval
Now that Opdivo (nivolumab) has been FDA approved for two cancer types, many patients are wondering: what’s…
-
CRI’s James Allison, Arming the Immune System
The director of CRI's Scientific Advisory Council talks immunotherapy with the New York Times.
-
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…
-
Across the CEO’s Desk: February 2015 Roundup
CRI's CEO Jill O'Donnell-Tormey, PhD, shares some of the latest news in cancer immunotherapy.
-
CRI’s Impact on Colorectal Cancer Immunotherapy
CRI scientists have contributed significantly to the immunological understanding and treatment of colorectal cancer.
-
Five Myths about Clinical Trials that Just Won’t Go Away
Curious about what happens when you enroll in a clinical trial? Hear firsthand about one woman's experience.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.